Digital Pathology Scoring of Immunohistochemical Staining Reliably Identifies Prognostic Markers and Anatomical Associations in a Large Cohort of Oral Cancers

Utilizing digital pathology algorithms for the objective quantification of immunohistochemical staining, this study aimed to identify robust prognostic biomarkers for oral cancer. Tissue microarrays with specimens of a large cohort of oral squamous cell carcinoma (n=222) were immunohistochemically stained to determine the expression of PD-L1, EGFR, and COX-2 and the amount of infiltrating NK cells and CD8-positive T cells. Immunoreactivity scores were assessed using both a classical manual scoring procedure and a digital semi-automatic approach using QuPath. Digital scoring was successful in quantifying the expression levels of different prognostic biomarkers (CD8: p<0.001; NK cells: p=0.002, PD-L1: p=0.026) and high levels of concordance with manual scoring results were observed. A combined score integrating EGFR expression, neck node status and immune cell signatures with a significant impact on overall and progression-free survival was identified (p<0.001). These data may contribute to the ongoing research on the identification of reliable and clinically relevant biomarkers for the individualization of primary and adjuvant treatment in oral cancer.

[1]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[2]  Zhenggang Chen,et al.  Diagnostic and therapeutic role of microRNAs in oral cancer , 2020, Oncology reports.

[3]  E. Jaffee,et al.  Tumor Mutational Burden, Toxicity, and Response of Immune Checkpoint Inhibitors Targeting PD(L)1, CTLA-4, and Combination: A Meta-regression Analysis , 2020, Clinical Cancer Research.

[4]  P. Ramos-García,et al.  Prognostic and clinicopathological significance of PD-L1 overexpression in oral squamous cell carcinoma: A systematic review and comprehensive meta-analysis. , 2020, Oral oncology.

[5]  R. Eils,et al.  Integrative Analysis of Multi-omics Data Identified EGFR and PTGS2 as Key Nodes in a Gene Regulatory Network Related to Immune Phenotypes in Head and Neck Cancer , 2020, Clinical Cancer Research.

[6]  A. Mäkitie,et al.  Overall assessment of tumor-infiltrating lymphocytes in head and neck squamous cell carcinoma: time to take notice , 2020, Acta oto-laryngologica.

[7]  P. Ettmayer,et al.  Selective and Potent CDK8/19 Inhibitors Enhance NK-Cell Activity and Promote Tumor Surveillance , 2020, Molecular Cancer Therapeutics.

[8]  J. Rajguru,et al.  Tumor markers in oral cancer: A review , 2020, Journal of family medicine and primary care.

[9]  C. R. Leemans,et al.  Digital pathology-aided assessment of tumor-infiltrating T lymphocytes in advanced stage, HPV-negative head and neck tumors , 2020, Cancer Immunology, Immunotherapy.

[10]  Hung-Ming Wang,et al.  Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study , 2019, The Lancet.

[11]  Victoria Sanz-Moreno,et al.  Faculty Opinions recommendation of QuPath: Open source software for digital pathology image analysis. , 2019, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[12]  Nasir M. Rajpoot,et al.  A Novel Digital Score for Abundance of Tumour Infiltrating Lymphocytes Predicts Disease Free Survival in Oral Squamous Cell Carcinoma , 2019, Scientific Reports.

[13]  E. Herpel,et al.  Upregulation of PD‐L1 and PD‐L2 in neck node metastases of head and neck squamous cell carcinoma , 2019, Head & neck.

[14]  T. Salo,et al.  Assessment of Tumor-infiltrating Lymphocytes Predicts the Behavior of Early-stage Oral Tongue Cancer , 2019, The American journal of surgical pathology.

[15]  C. von Buchwald,et al.  Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma , 2019, British Journal of Cancer.

[16]  C. Brennan,et al.  Tumor mutational load predicts survival after immunotherapy across multiple cancer types , 2019, Nature Genetics.

[17]  O. V. Matorin,et al.  Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study , 2019, The Lancet.

[18]  M. Salto‐Tellez,et al.  Automated Tumour Recognition and Digital Pathology Scoring Unravels New Role for PD-L1 in Predicting Good Outcome in ER-/HER2+ Breast Cancer , 2018, Journal of oncology.

[19]  A. Gonzalez-Perez,et al.  NK Cell Infiltrates and HLA Class I Expression in Primary HER2+ Breast Cancer Predict and Uncouple Pathological Response and Disease-free Survival , 2018, Clinical Cancer Research.

[20]  Juan Shen,et al.  Prognostic and predictive values of immune infiltrate in patients with head and neck squamous cell carcinoma. , 2018, Human pathology.

[21]  M. Najafi,et al.  Cyclooxygenase‐2 in cancer: A review , 2018, Journal of cellular physiology.

[22]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[23]  H. Woodrow,et al.  : A Review of the , 2018 .

[24]  E. Richardsen,et al.  Evaluation of tumor-infiltrating lymphocytes using routine H&E slides predicts patient survival in resected non-small cell lung cancer. , 2018, Human pathology.

[25]  P. Ferroli,et al.  Survival gain in glioblastoma patients treated with dendritic cell immunotherapy is associated with increased NK but not CD8+ T cell activation in the presence of adjuvant temozolomide , 2017, Oncoimmunology.

[26]  K. Jakubowska,et al.  Stromal and intraepithelial tumor-infiltrating lymphocytes in colorectal carcinoma , 2017, Oncology letters.

[27]  P. Pharoah,et al.  Association between tumour infiltrating lymphocytes, histotype and clinical outcome in epithelial ovarian cancer , 2017, BMC Cancer.

[28]  K. Harrington,et al.  Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. , 2017, The Lancet. Oncology.

[29]  Laurence Zitvogel,et al.  The immune contexture in cancer prognosis and treatment , 2017, Nature Reviews Clinical Oncology.

[30]  Zhengxue Han,et al.  Prognostic Value of Tumor-Infiltrating Lymphocytes for Patients With Head and Neck Squamous Cell Carcinoma , 2016, Translational oncology.

[31]  K. Harrington,et al.  Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. , 2016, The New England journal of medicine.

[32]  J. Lunceford,et al.  Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. , 2016, The Lancet. Oncology.

[33]  Sudeep Gupta,et al.  Elective versus Therapeutic Neck Dissection in Node-Negative Oral Cancer. , 2015, The New England journal of medicine.

[34]  R. Childs,et al.  Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens , 2015, Nature Reviews Drug Discovery.

[35]  Zhao Lu,et al.  Role of EGFR as a prognostic factor for survival in head and neck cancer: a meta-analysis , 2014, Tumor Biology.

[36]  C. Rödel,et al.  Tumor-infiltrating lymphocytes favor the response to chemoradiotherapy of head and neck cancer , 2014, Oncoimmunology.

[37]  F. Marincola,et al.  Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours , 2013, The Journal of pathology.

[38]  E. King,et al.  Tumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer , 2013, British Journal of Cancer.

[39]  C. Rödel,et al.  Tumour-infiltrating lymphocytes predict response to definitive chemoradiotherapy in head and neck cancer , 2013, British Journal of Cancer.

[40]  J. Galon,et al.  From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer. , 2013, Current opinion in immunology.

[41]  C. Sautès-Fridman,et al.  The immune contexture in human tumours: impact on clinical outcome , 2012, Nature Reviews Cancer.

[42]  G. D. de Bock,et al.  The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis , 2011, British Journal of Cancer.

[43]  M. Caligiuri,et al.  Innate or Adaptive Immunity? The Example of Natural Killer Cells , 2011, Science.

[44]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[45]  M. Karamouzis,et al.  Faculty Opinions recommendation of Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. , 2009 .

[46]  J. Pignon,et al.  Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[47]  C. Bokemeyer,et al.  Platinum-based chemotherapy plus cetuximab in head and neck cancer. , 2008, The New England journal of medicine.

[48]  M. Caligiuri,et al.  Human natural killer cells. , 2008, Blood.

[49]  F. Schmidt Meta-Analysis , 2008 .

[50]  M. Ikram,et al.  Neck involvement in early carcinoma of tongue. Is elective neck dissection warranted? , 2007, JPMA. The Journal of the Pakistan Medical Association.

[51]  Axel Benner,et al.  Tissue microarray analysis reveals site-specific prevalence of oncogene amplifications in head and neck squamous cell carcinoma. , 2003, Cancer research.

[52]  D. Sidransky,et al.  Head and neck cancer. , 2001, The New England journal of medicine.

[53]  R. Lima,et al.  Supraomohyoid neck dissection in the treatment of T1/T2 squamous cell carcinoma of oral cavity. , 1994, American journal of surgery.

[54]  Jian-yong Li,et al.  Low absolute NK cell counts in peripheral blood are associated with inferior survival in patients with mantle cell lymphoma. , 2019, Cancer biomarkers : section A of Disease markers.

[55]  A. Jemal,et al.  Cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.

[56]  Jacques Ferlay,et al.  The global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2012 , 2017, CA: a cancer journal for clinicians.

[57]  藤倉雄二,et al.  わが国における成人市中肺炎原因微生物についてのsystematic review/meta‐analysis , 2016 .

[58]  Rbcafe The Force Awakens , 2015 .

[59]  R. Singh,et al.  Demographic risk factors, affected anatomical sites and clinicopathological profile for oral squamous cell carcinoma in a north Indian population. , 2014, Asian Pacific journal of cancer prevention : APJCP.